- Browse by Subject
Browsing by Subject "[11C]Halo-GSK1482160 (F-, Br-, and I-)"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Item Synthesis and in vitro biological evaluation of new P2X7R radioligands [11C]halo-GSK1482160 analogs(Elsevier, 2019-06) Gao, Mingzhang; Wang, Min; Meyer, Jill A.; Territo, Paul R.; Hutchins, Gary D.; Zarrinmayeh, Hamideh; Zheng, Qi-Huang; Radiology and Imaging Sciences, School of MedicineThe reference standards halo-GSK1482160 (F-, Br-, and I-) and their corresponding precursors desmethyl-halo-GSK1482160 (F-, Br-, and I-) were synthesized from (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid or (S)-5-oxopyrrolidine-2-carboxylic acid and 2-halo-3-(trifluoromethyl)benzylamine (F-, Br-, and I-) in one step with 45–93% yields. The target tracers [11C]halo-GSK1482160 (F-, Br-, and I-) were prepared from desmethyl-halo-GSK1482160 (F-, Br-, and I-) with [11C]CH3OTf under basic conditions (NaOH-Na2CO3, solid, w/w 1:2) through N-[11C]methylation and isolated by HPLC combined with SPE in 40–50% decay corrected radiochemical yield. The radiochemical purity was >99%, and the molar activity (AM) at end of bombardment (EOB) was 370–740 GBq/μmol. The potency of halo-GSK1482160 (F-, Br-, and I-) in comparison with GSK1482160 (Cl-) was determined by a radioligand competitive binding assay using [11C]GSK1482160, and the binding affinity Ki values for halo-GSK1482160 (F-, Br-, and I-) and GSK1482160 (Cl-) are 54.2, 2.5, 1.9 and 3.1 nM, respectively.